Polo-like kinase 1 (Plk1) regulates mitotic progression in all eukaryotes and has been implicated in the transformation of human cells. Analysis of the cytological and anti-tumor activities of BI 2536, a novel, selective pharmacological inhibitor of Plk1, has connected chemistry and biology to the bedside
Cervical adenocarcinoma is one of the most common gynecological malignancies. Despite the improvemen...
Polo-like kinase 1(Plk1)is an evolutionarily conserved serine/threonine kinase in mammalian cells th...
Objective BI6727, an ATP-competitive PLK1 inhibitor, has been shown to cause cell death in multi-tum...
SummaryFine-mapping of the cell-division cycle, notably the identification of mitotic kinase signali...
Polo-like kinase 1 (Plk1) regulates mitotic progression in all eukaryotes and has been implicated in...
The mitotic kinases, Cdk1, Aurora A/B, and Polo-like kinase 1 (Plk1) have been characterized extensi...
SummaryFine-mapping of the cell-division cycle, notably the identification of mitotic kinase signali...
Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tacti...
Because multiple cancers require Polo-like kinase (Plk) 1 for survival [1-3], Plk1 has been investig...
BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under cli...
Abstract Polo-like kinase 1 (Plk1) is an interesting molecule both as a biomarker and as a target fo...
BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under cli...
Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tacti...
Polo-like kinase 1(PLK1) is crucial for cell mitosis.Over-expression of PLK1 has been ob-served in m...
Polo-like kinase 1 (PLK1), a member of the Polo-like kinase family, plays an important regulatory ro...
Cervical adenocarcinoma is one of the most common gynecological malignancies. Despite the improvemen...
Polo-like kinase 1(Plk1)is an evolutionarily conserved serine/threonine kinase in mammalian cells th...
Objective BI6727, an ATP-competitive PLK1 inhibitor, has been shown to cause cell death in multi-tum...
SummaryFine-mapping of the cell-division cycle, notably the identification of mitotic kinase signali...
Polo-like kinase 1 (Plk1) regulates mitotic progression in all eukaryotes and has been implicated in...
The mitotic kinases, Cdk1, Aurora A/B, and Polo-like kinase 1 (Plk1) have been characterized extensi...
SummaryFine-mapping of the cell-division cycle, notably the identification of mitotic kinase signali...
Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tacti...
Because multiple cancers require Polo-like kinase (Plk) 1 for survival [1-3], Plk1 has been investig...
BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under cli...
Abstract Polo-like kinase 1 (Plk1) is an interesting molecule both as a biomarker and as a target fo...
BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under cli...
Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tacti...
Polo-like kinase 1(PLK1) is crucial for cell mitosis.Over-expression of PLK1 has been ob-served in m...
Polo-like kinase 1 (PLK1), a member of the Polo-like kinase family, plays an important regulatory ro...
Cervical adenocarcinoma is one of the most common gynecological malignancies. Despite the improvemen...
Polo-like kinase 1(Plk1)is an evolutionarily conserved serine/threonine kinase in mammalian cells th...
Objective BI6727, an ATP-competitive PLK1 inhibitor, has been shown to cause cell death in multi-tum...
DOI
Add to ORKG